Vector Development

Unarmed Agent Well Tolerated In Dog Study

Published in Gene Therapy Weekly, June 14th, 2001

Vion Pharmaceuticals, Inc. (VION) says initial results of a research study in 33 dogs with advanced cancers that received increasing intravenous doses of "unarmed" Tapet^R vector (VNP20009) showed that this vector was well tolerated.

The intent of the research was to determine the safety and maximum tolerated dose of weekly or every-other-week injections of VNP20009, and to assess the behavior of VNP20009 in a large species that is similar to humans and that develops naturally occurring tumors.

The study demonstrated that VNP20009 was safe to administer on a weekly or every-other-week schedule and also produced significant antitumor...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (2001-06-14)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry